Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Mirabegron Recommended for Approval for Treatment of OAB
June 13, 2011
- DSP, Kyorin Announce Results of Domestic PII Trial of Ranirestat
June 13, 2011
- Ajinomoto: Pharma Operating Profits Down 32% due to Higher R&D Costs
June 13, 2011
- Korosho to Conduct Survey on Economic Conditions in Healthcare
June 13, 2011
- KW-6002 Found Effective for PD in Domestic PIII Study: Kyowa Kirin
June 13, 2011
- Asahi Kasei Pharma: Sales Up 3.4% Driven by 3.5-Fold Increase in Sales of Recomodulin
June 13, 2011
- Council to Discuss Revision of Copayments for OTC-like Drugs
June 13, 2011
- JAK Inhibitor Tofacitinib Reduces Symptoms of RA: Pfizer Inc.
June 13, 2011
- ASKA: First Net Loss since Merger due to Earthquake
June 13, 2011
- Industry FTC Revises GL on Business Entertainment Practices
June 13, 2011
- Taiyo to Announce New Business Strategy around October
June 13, 2011
- Torii: Double-digit Decreases in Profits
June 13, 2011
- CHMP Recommends Approval for Astellas' Antibiotic Vibativ
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Nippon Chemiphar: Sales Up 14% Driven by Generics
June 13, 2011
- PMDA Proposes Fees for Regulatory Strategy Consultation Services
June 13, 2011
- FDA Approves GE Versions of Aricept from 15 Companies
June 13, 2011
- Seikagaku: Net profits Down 31.4% due to Impact of Disaster
June 13, 2011
- METI to Relax Power Use Restriction for Drug-related Companies
June 13, 2011
- JAMS, PSJ to Directly Exchange Opinions on Switch OTC Drug Candidates
June 13, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…